Insider Insights
01.02.2022
Proposals for reforming public and private health

The report looks at four possible scenarios including most notably the creation of a “grande Sécu...

Read more
Insider Insights
01.02.2022
Orphan drugs not included in reference price order

The Court has annulled the inclusion of the orphan drug Onivyde (irinotecan) in the reference price ...

Read more
Insider Insights
01.02.2022
Proposals aimed at building together our future

The association proposes concentrating efforts around four primary objectives.

Read more
Insider Insights
01.02.2022
Germany completes early benefit assessments

In addition to new cancer drugs, the G-BA also evaluated the first antiviral drug to treat COVID-19 ...

Read more
Insider Insights
01.02.2022
Early access granted to Xevudy

Notably, the early access scheme was reformed with effect from 1st July 2021.

Read more
Insider Insights
01.02.2022
NICEs new methods and processes manual

The National Institute for Health and Care Excellence (NICE) on 31st January 2022 published its new ...

Read more
Insider Insights
01.02.2022
Prescribing controls on new medicines

The Ministry of Health reports that 65.1% of medicines admitted to reimbursement in 2021 were subjec...

Read more
Articles
27.01.2022
Early access schemes in France

The 2021 Social Security Law made provision for overhauling the early scheme in France. As of 1st Ju...

Read more
Articles
25.01.2022
PMA Perspectives Q1 2022

We hope you’ve had a wonderful start to the New Year and we’d love to welcome you to our fourth ...

Read more
Articles
20.01.2022
Orphan drugs market access

According to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo a r...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.